ABSTRACT. Matrix metallopeptidase 1 (MMP-1) has been reported to be involved in the coexistence of type 2 diabetes mellitus (T2DM) and coronary heart disease (CHD). We sought to examine the association between the MMP-1 gene polymorphism and coexistence of T2DM and CHD in a Han Chinese population. We extracted genomic DNA from the peripheral blood of 794 subjects, including 378 patients with coexisting T2DM and CHD and 416 healthy controls. We selected several single nucleotide polymorphisms of the MMP-1 gene and genotyped them using the MassARRAY system, before analyzing the data with Haploview 4.0 and SPSS 20.0. A statistical difference was found in the distribution of rs1799750 genotypes between the patient and control groups (P = 0.041). The frequency of the 2G/2G genotype was 44.25 and 37.0% among patients and control subjects, respectively. Moreover, the frequency of the 2G allele was 65.9% among patients and 59.6% in the control group, and this difference was found to be significant (P = 0.010). Elevated body mass index was also associated with the 2G/2G genotype. Thus, MMP-1 rs1799750 may be involved in the development of coexisting T2DM and CHD in the Han Chinese population.
INTRODUCTION
Type 2 diabetes mellitus (T2DM) frequently coexists with coronary heart disease (CHD) (El-Atat et al., 2004) . Increased release of free fatty acids induces the generation of reactive oxygen species (ROS) and elevates oxidative stress in T2DM patients, leading to endothelial dysfunction and promoting the occurrence of CHD (Meerarani et al., 2006) . Therefore, T2DM and CHD may interact in patients to intensify the severity of both diseases. However, the exact mechanisms underlying this interaction remain unclear.
Matrix metalloproteinases (MMPs) are endopeptidases that depend upon calcium (Ca 2+ ) and contain zinc (Zn 2+ ). They belong to a large, highly structurally homologous group of proteases known as the metzincin superfamily (Nagase and Woessner, 1999) . These zincpeptidase enzymes use hydrolysis to degrade various extracellular matrix proteins, and are known to be involved in tissue reconstruction and repair, cell migration, angiogenesis, chronic inflammatory reactions, wound healing, and tumor invasion and metastasis (Vu and Werb, 2000; Visse and Nagase, 2003) . Matrix metallopeptidase 1 (MMP-1) forms part of an MMP gene cluster on chromosome 11q22.3. It encodes a secreted enzyme that breaks down interstitial collagen types I, II, and III. MMP-1 can thin and disrupt the fibrous cap of atherosclerotic plaques (Nikkari et al., 1995) , and thus may be associated with coronary atherosclerosis, a condition that can easily lead to CHD.
The 1G/2G polymorphism of MMP-1 has been reported to be associated with CHD in Caucasian populations (Ye et al., 2003) . In addition, high glucose concentrations in endothelial cells and macrophages have been shown to increase MMP-1 expression and activity (Death et al., 2003) . Heightened glucose concentration also disrupts certain intracellular signal transduction pathways, such as those involving ROS that activate MMP-1 expression (King and Wakasaki, 1999; Li and Karin, 1999) . Therefore, we speculated that MMP-1 might be associated with coexisting T2DM and CHD.
We chose six single nucleotide polymorphisms (SNPs) of the MMP-1 gene to study: rs1799750, rs498186, rs996999, rs2071232, rs1938901, and rs2239008. rs1799750 and rs498186 are located in the MMP-1 promoter, whereas rs2239008 lies within the 3'-untranslated region. The remainder are located in introns or the untranslated region.
MATERIAL AND METHODS

Subjects
A total of 378 patients were recruited from our hospital. T2DM diagnoses were made at least six months before enrolment in this study. Patients were defined as diabetic according to: 1) a report of having been informed of having diabetes, and/or 2) use of oral hypoglycemic drugs or insulin, or 3) a fasting plasma glucose level ≥126 mg/dL, or 4) a 2-h oral glucose tolerance test result ≥200 mg/dL. CHD was diagnosed if patients had a history of myocardial infarction or showed abnormal electrocardiographic results. The control group consisted of 416 unrelated healthy subjects having undergone health examinations at our hospital. The study was approved by the local ethics committee, and written informed consent was obtained from all subjects prior to participation.
Genotyping
Peripheral blood was drawn from a vein into a sterile tube containing ethylenediamine tetraacetic acid. Plasma samples were stored at -20°C. Genomic DNA was extracted from frozen peripheral blood samples using a QIAamp Blood Mini Kit (QIAGEN Inc., Valencia, CA, USA) following the manufacturer protocol. Genotyping of all SNPs was performed using the MassARRAY platform (Sequenom, San Diego, CA, USA). Primer extension and polymerase chain reaction were performed using iPLEX enzyme (Sequenom) and HotStarTaq DNA polymerase (QIAGEN, Hilden, Germany), following manufacturer protocols. The resulting spectra were processed with MassARRAY RT software (version 3.0.0.4), and genotype data were analyzed using the MassARRAY Typer program (version 3.4; Sequenom).
Statistical analysis
All data were analyzed using SPSS 20.0 (IBM Corp., Armonk, NY, USA). Allele and genotype frequencies for each polymorphism and Hardy-Weinberg equilibrium were evaluated by chi-square tests. The association between CHD and each polymorphism was analyzed using chi-square tests or Fisher's exact tests. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess the strength of the association between allele frequencies and CHD. Pairwise linkage disequilibrium (LD) statistics (D' and r 2 ) and haplotype frequencies were computed using Haploview 4.0 (Broad Institute, Cambridge, MA, USA) to construct haplotype blocks.
RESULTS
All observed genotype distributions in both patient and control groups were in line with Hardy-Weinberg equilibrium (P > 0.05). Strong LD was detected in relation to two pairs of SNPs (rs2239008-rs1938901 and rs996999-rs498186), which formed two haplotype blocks (D' > 0.9, Figure 1 ). Genotype distributions, allelic frequencies, and haplotypes in the patient and control groups are shown in Tables 1-3. A statistical difference between the two groups was found in the distribution of MMP-1 gene rs1799750 genotypes (P = 0.041). The frequency of the 2G/2G genotype was 44.2% in patients, and 37.0% among the controls (Table 2) . Moreover, the distribution of rs1799750 alleles significantly differed between the patient and control groups (P = 0.010). In the former, the frequency of the 2G allele was 65.9%, while in the latter it was 59.6% (Table 1) . Furthermore, we performed an association analysis to determine whether the haplotypes identified were associated with T2DM-CHD risk. However, these haplotypes did not differ between patients and controls (Table 3) . Finally, we analyzed the association between rs1799750 genotype and ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 15 (2): gmr.15027938 certain clinical characteristics among members of the patient group. The 2G/2G genotype was found to be associated with higher body mass index (BMI; Table 4 ). 
DISCUSSION
Significant evidence exists showing that high blood glucose is a primary risk factor for cardiovascular disease (King and Wakasaki, 1999; Li and Karin, 1999) . T2DM patients suffering from CHD are at increased risk of mortality compared to those without CHD (Kannel and McGee, 1979; Fuller et al., 1983) .
Levels of MMPs are elevated in cultivated diabetic fibroblasts compared with those from healthy controls. This is significant because these cells play an important role in wound healing (Lobmann et al., 2006) . In endothelial cells and macrophages from diabetes patients, high glucose levels increase the expression of MMPs and promote CHD (Death et al., 2003) . In addition, diabetes mellitus enhances vascular MMP activity and increases the likelihood of developing CHD, as it is mediated by a ROS-sensitive pathway (Uemura et al., 2001; Ye et al., 2003) . The above-cited evidence shows that T2DM-CHD coexistence may be associated with MMP activity.
In this study, we found that the MMP-1 gene rs1799750 polymorphism was associated with coexisting T2DM and CHD. The body of research relating to this polymorphism has been growing in recent years. rs1799750 is located in the MMP-1 promoter region, and its 2G allele is known to increase transcription of this gene (Rutter et al., 1998; Affara et al., 2011) . This MMP-1 1G/2G polymorphism may influence the prevalence of CHD (Ye et al., 2003; Horne et al., 2007) . Moreover, it has been associated with coexisting T2DM and CHD in Caucasian populations, and the 2G allele is present at a higher frequency in these patients than in healthy
